Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for food industry professionals · Friday, March 29, 2024 · 699,743,958 Articles · 3+ Million Readers

Pediatric Epilepsy Therapeutics Markets, 2019-2023 - The Global Industry is Dominated by Eisai, GlaxoSmithKline, GW Pharmaceuticals, Pfizer, and UCB

Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Pediatric Epilepsy Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.



The pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.


The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures.


Increasing demand for second and third-generation AEDs

The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.

Adverse side effects and increasing social stigma

The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.


Key Players

  • Eisai
  • GlaxoSmithKline
  • GW Pharmaceuticals
  • Pfizer
  • UCB

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS


PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Second-generation anti-epileptics - Market size and forecast 2018-2023
  • Third-generation anti-epileptics - Market size and forecast 2018-2023
  • First-generation anti-epileptics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES


PART 11: MARKET TRENDS


PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eisai
  • GlaxoSmithKline
  • GW Pharmaceuticals
  • Pfizer
  • UCB

For more information about this report visit https://www.researchandmarkets.com/research/tmlk9j/pediatric?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Central Nervous System Drugs , Pediatrics
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release